Retrospective Study Shows Nivolumab Associated With OS Benefit After Nivolumab/Ipilimumab irAEs in Advanced Melanoma
Source: OncLive, November 2023
Elizabeth I. Buchbinder, MD, discusses findings from a retrospective study evaluating the resumption of nivolumab maintenance therapy in patients with advanced melanoma who discontinued treatment with the combination of nivolumab and ipilimumab due to immune-related adverse effects.
Maintenance treatment with nivolumab (Opdivo) monotherapy was associated with improved overall survival (OS) vs the permanent discontinuation of nivolumab in patients with advanced melanoma following a treatment hold of the combination of nivolumab and ipilimumab (Yervoy) due to immune-related adverse effects (irAEs), according to data from a retrospective study presented at the 2023 ASCO Annual Meeting.
Findings indicated that patients who resumed nivolumab monotherapy after the resolution of toxicity and completion of steroid taper (n = 46) experienced a 68% reduction in the risk of death compared with those who did not resume nivolumab (n = 76; HR, 0.32; 95% CI, 0.12-0.84).